| 31 Mai 2013
A new study conducted in an ethnically diverse and predominantly low  income population found that only one-fifth of rheumatoid arthritis  (RA) patients had an overall adherence rate to prescribed oral  medications at 80% or greater.  Findings published today in  Arthritis & Rheumatism,  a journal of the American College of Rheumatology (ACR), indicate that  less than two thirds of medication regimens for non-biologic disease  modifying anti-rheumatic drugs (DMARDs) were correctly followed by RA  patients. 
According to ACR estimates, more than one million U.S. adults experience inflammation, pain, tenderness and swelling of the joints caused by RA. While there have been advances in RA treatments—biologic therapies such as the tumor necrosis factor (TNF) inhibitors adalimumab (Humira®), etanercept (Enbrel®), and infliximab (Remicade®)—oral DMARDS, namely methotrexate, remain the gold standard for treating those with RA. In fact, previous research has shown that biologics are more effective when taken with methotrexate, but patients must follow the prescribed medicine regimens to realize the full benefits.
For the present study, Drs. Christian Waimann, Maria Suarez-Almazor and colleagues from The University of Texas MD Anderson Cancer Center, in Houston enrolled 107 RA patients in a two-year study that electronically monitored their intake of oral RA medications. Measures of DMARD adherence were:
    Of those who participated, 87% were female with a mean disease  activity of 8 years.   The RA patient group was ethnically diverse with  65% Hispanic, 19% African-American and 16% Caucasian.  Educational  status was low with 45% not completing high school and 67% having  incomes less than $20,000.  RA  patients who took their medications as prescribed were considered  adherent—64% for DMARD therapy and 70% for prednisone.  Only 21% of  participants adhered to their DMARD therapy and 41% correctly took  prednisone at least 80% of the time.  Patients who took their  medications as prescribed showed significantly lower disease activity  scores (DAS28 at 3.3) throughout the study period compared to those who  were less adherent (DAS28 at 4.1).  Increases in radiological damage  score were also higher in RA patients who were non-adherent.  Researchers  report that adherence to oral DMARDs and steroid therapy in RA patients  with RA was low, ranging from 58% to 71%, but patients who had better  mental health status and were not widowed or separated were more likely  to adhere to their medication regimen. “Our study is the first to  measure drug adherence in RA patients over the long-term, and emphasizes  the importance of following the prescribed regimen to manage their  disease,” concludes Dr. Suarez-Almazor.  “Physicians should work with  patients to understand their reasons for non-adherence and discuss the  importance of taking medications as prescribed to control RA symptoms  and prevent disease progression.”